接受免疫球蛋白家庭输液的 Option Care 患者得益于更好的疗效、更低的成本
By: Option Care
November 12, 2015
SAN ANTONIO — Option Care patients treated with immunoglobulin (IG) therapy at home with a high level of clinical oversight had better outcomes compared to others receiving the therapy according to a first-of-its-kind study presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting this week. The researchers, who evaluated data from Option Care as compared to a large national database, also determined that the cost of therapy was lower. [*]Orange J, Kirkham H, Ayer G, et al. Improved clinical outcomes for patients receiving immunoglobulin therapy through specialty pharmacy or home infusion services. Paper presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2015 Annual Scientific Meeting: Nov 5-9, 2015; San Antonio.
One of the nation’s largest providers of home and alternate treatment site infusion services, Option Care provides high-quality, high-touch clinical support to patients undergoing treatment for complex conditions, including those receiving IG. Option Care’s unique treatment model combines locally delivered care with nationally managed treatment protocols and outcomes data collection. Specially trained infusion nurses and pharmacists provide individualized, expert IG treatment and patient education in the home. Patient-reported outcome measures — a scientific way of capturing patient experience — are collected by a dedicated team of IG experts and shared with patient’s broader health care team to keep everyone on the same page about the patient’s health status and to optimize the treatment plan.
“We conducted this research to test the hypothesis that patients who receive higher levels of clinical care in the home end up having better outcomes, ” said Jordan Orange, M.D., Ph.D., lead investigator of the study and professor of pediatrics and immunology at Baylor College of Medicine in Houston. “We found that the provision of comprehensive and consistent care in a patient’s own home does indeed lead to better outcomes. And an added benefit was that it was actually more cost effective.”
IG 疗法的提供对象是免疫系统疾病患者，如免疫缺陷或自身免疫性疾病（包括某些神经肌肉疾病）患者。治疗的护理地点可以是医院住院部、医院门诊输液中心、医生办公室、社区输液中心或家中。
在一项从 2011 年 8 月 1 日至 2014 年 6 月 30 日的回顾性研究中，Orange 博士和他的同事评估了接受家庭 IG 疗法的 Option Care 患者与一个大型国家行政索赔数据库 (IMS Pharmetrics Plus) 中所包含对照组患者的疗效对比。患者以两种方式之一接受治疗：直接注射到血液中的静脉 IG (IVIG) 和注射到第一层皮肤下方的皮下 IG (SCIG)。研究人员将每名 Option Care 患者与数据库中的四名患者进行配对：227 名 Option Care IVIG 患者与 908 名对照组患者相比较，59 名 Option Care SCIG 患者与 236 名对照组患者相比较。研究人员发现：
- Serious bacterial infections were lower in Option Care IVIG patients (.16 per patient per year) compared to control IVIG patients (.29 per patient per year)[*]Orange J, Kirkham H, Ayer G, et al. Improved clinical outcomes for patients receiving immunoglobulin therapy through specialty pharmacy or home infusion services. Paper presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2015 Annual Scientific Meeting: Nov 5-9, 2015; San Antonio.
- Serious adverse events (renal impairment, hepatitis, anaphylaxis and aseptic meningitis) were lower in Option Care SCIG patients (.08 per patient per year) compared to SCIG control patients (.34 per patient per year). [*]Orange J, Kirkham H, Ayer G, et al. Improved clinical outcomes for patients receiving immunoglobulin therapy through specialty pharmacy or home infusion services. Paper presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2015 Annual Scientific Meeting: Nov 5-9, 2015; San Antonio.
- Costs were lower overall for Option Care IVIG patients compared to controls ($112,756 vs. $120,567 per patient per year).[*]Orange J, Kirkham H, Ayer G, et al. Improved clinical outcomes for patients receiving immunoglobulin therapy through specialty pharmacy or home infusion services. Paper presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2015 Annual Scientific Meeting: Nov 5-9, 2015; San Antonio.
“Delivering high quality care for all of our patients is our top priority. We believe that our high-touch care model benefits patients, and we are pleased that this IG data bears that out,” said Paul Mastrapa, CEO of Option Care. “Not only do our patients appreciate the quality of life benefits of receiving care in the home, this research shows they also are getting the best quality care at a lower cost.”
关于美国过敏、哮喘和免疫学会 (ACAAI)
The ACAAI is a professional medical organization of more than 6,000 allergists-immunologists and allied health professionals, headquartered in Arlington Heights, Ill. The College fosters a culture of collaboration and congeniality in which its members work together and with others toward the common goals of patient care, education, advocacy and research. ACAAI allergists are board-certified physicians trained to diagnose allergies and asthma, administer immunotherapy, and provide patients with the best treatment outcomes. For more information and to find relief, visit www.AllergyandAsthmaRelief.org.
关于 Option Care
Option Care Enterprises, Inc.（前身为 Walgreens Infusion Services）由经过专门培训的输液护士、药剂师和营养师提供高品质的临床护理，医治各式急性、慢性和罕见疾病的患者。作为全美最大的家庭和备选医疗站点输液服务提供者之一，Option Care 在美国各地拥有 92 家输液药房和 110 个备选医疗站点。有关详情请访问 www.OptionCare.com。
# # #
媒体联系人信息
Option Care
Lauren Kotarski
312-558-1770
LKotarski@pcipr.com
You might also be interested in:
Option Care 支持项目的临床干预改善了家庭护理且防止住院，节省了数百万美元
AUSTIN, Texas — Option Care’s local dietitian-led Nutrition Support Team improves the care of patients receiving nutrition therapy at home and saves millions in costs by preventing hospitalization, according to a study being presented at the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Clinical Nutrition Week meeting today in Austin. The study tracked the […]
Option Care Selected as the Home and Alternate Site Infusion Provider for Newly Approved Breakthrough Therapy, Trogarzo (ibalizumab-uiyk) Injection
BANNOCKBURN, Ill., March 9, 2018 — Option Care Enterprises, Inc., the nation’s largest independent provider of home and alternate treatment site infusion services, has been selected by Theratechnologies Inc. as an infusion provider for TrogarzoTM (ibalizumab-uiyk) Injection, an intravenous (IV) infusion for the treatment of multidrug resistant human immunodeficiency virus type 1 (HIV-1) infections. Option […]